Abstract: Spirometry is diffi cult for some COPD patient to perform. Volumetric capnography could be a second choice test to evaluate the severity of functional disturbances. The aim of this work is to test this hypothesis. A total number of 98 subjects were classifi ed either as normal ex-smokers (N = 14) or COPD patients. The latter were staged following GOLD recommendations. Spirometry and volumetric capnography recordings were obtained from each patient. ANOCOVA analysis IAH showed the greatest association with stage (F > 40), with no significant covariant dependence on V T . A receiver operating characteristics curve analysis showed values of the area under the curve greater than 0.9 for IAH and IVE at all stage levels, with a sensitivity = specifi city value greater than 80%. We conclude that IAH and IVE can be used when spirometry cannot be reliably performed, as an alternative test to evaluate the degree of functional involvement in COPD patients.
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Introduction
Stable chronic obstructive pulmonary disease (COPD) can be evaluated by means of standard spirometry in a large majority of patients. In fact, spirometry is the gold standard to diagnose and classify COPD patients, and the severity of the disease. When properly performed, spirometry is the most reproducible, standardized and objective way of measuring fl ow limitation. A correct spirometry manoeuvre, however, requires the ability to clearly understand the manoeuvre, the intellectual capacity to perform it, and the absence of clinical limitations which might prevent several maximal forced expiratory manoeuvres from being performed. It is relatively common to deal with subjects with disabled intellectual capacity, with language diffi culties, or clinical situations that make the forced expiratory manoeuvres painful or may even preclude them (chest pain, coronary vascular disease, minimal efforts dyspnoea, etc) In such cases spirometry is a poor cost/benefi t procedure. Other situations such as intubation or tracheotomy, or patients lying in bed also limit the application of standard spirometry.
Pulmonary heterogeneity is, together with airways obstruction, a cardinal feature in the functional impairment of COPD. Heterogeneity, mostly dependent of peripheral involvement, is seen to increase with the severity of the disease; therefore, volumetric capnography, a technique that basically explores regional distribution, can be expected to correlate with the severity of disease in COPD patients. Previous authors have outlined the good relationship between changes in volumetric capnography parameters and the severity of COPD (Kars et al 1995; Kars et al 1997; Wilschut et al 1999; and Koulouris et al 2001) ; however, the diagnostic value of volumetric capnography has not been systematically explored. Recent studies reduce the intrinsic variability of the parameters, either by using internal relationships (Romero 2001) , a procedure that reduces the noise-to-signal ratio, or by using the reference values reported by Åström et al (2000) in normal people.
Volumetric capnography parameters are measured in continuous scales. Their use as a diagnostic test requires the selection of a cut-off value in the original scale in order to defi ne positive and negative test outcome. Comparison of the dichotomised test results with the clinical status of the patient, evaluated as the disease stage from Global Initiative for Chronic Lung Disease (GOLD) classifi cation (a spirometry based criterion) (GOLD 2006) , allows estimation of the test's diagnostic sensitivity (Se) and specifi city (Sp), and determines the cut-off values that concurrently optimise Se and Sp. According to the hypothesis that volumetric capnography could be an alternative test to determine the amount of functional involvement in COPD patients, we have designed a study to compare the diagnostic value of volumetric capnography with spirometry as gold standard.
Methods

Subjects
A group of 84 patients (18 women, 66 men; age 60 ± 13 years, mean ± standard deviation) with clinical symptoms of COPD have been selected from patients attending the Pulmonary Function Laboratory. This protocol was approved by the Hospital's Research Committee. Patients were asked to give their consent for statistical use of the results of functional studies. The selection criteria were: clinical diagnosis of COPD based on clinical symptoms and history of exposure to cigarette smoking. Age limits were 30 to 80 years, and body mass index (BMI) was limited to 35. Exclusion criteria were cardiovascular comorbidity disease, sequelae of tuberculosis on the chest X-ray or any other coexistent lung disease, and neuromuscular or other diseases causing loss of ventilatory capacity. In order to exclude asthmatics, patients with a change of more than 12% in FEV 1 after bronchodilator were excluded. Subjects were classifi ed according to the Global Initiative for Chronic Lung Disease (GOLD) criteria (GOLD 2006) into fi ve groups: -Group 0 (N = 33) or subjects at risk, with normal spirometry (FEV%FEC Ն70%, FEV 1 %pred Ն80%), but symptoms (cough, sputum). -Group I (N = 1) or mild COPD, with FEV 1 %FVC Ͻ70%, but FEV 1 %pred Ͻ80%.
-Group II (N = 20) or moderate COPD, with FEV 1 %FVC < 70%, and 50% ՅFEV 1 %pred Ͻ80%. -Group III (N = 19) or moderate to severe COPD, with FEV 1 %FVC Ͻ70%, and 30% ՅFEV 1 %pred Ͻ50%. -Group IV (N = 18) or severe COPD, with FEV 1 %FVC Ͻ70%, and FEV 1 %pred Ͻ30%. In these fi ve groups FEV 1 and FVC post-bronchodilator in percent of predicted were considered. A group of 14 normal subjects (6 women, 8 men; age 48 ± 11 years, mean ± SD), ex-smokers (more than 10 years of cessation) but free of symptoms was also studied, and is called "Ex-Smok" Group. The same exclusion criteria were applied. Table 1 shows the descriptive and spirometric data for the different groups. All COPD subjects were in a stable situation, with no changes in respiratory symptoms during the month prior to the study, and no acute episodes of respiratory failure more than six months. Patients were asked not to have any inhaled therapy in the previous twelve hours. They sat down for at least half an hour before the procedure.
Instrumentation
The equipment used was a Cosmo Plus System (Novametrix Medical Systems Inc, Wallinford, CT, USA), which measures CO 2 concentration by means of a mainstream infrared cell, and airfl ow by an integrated pitot type pneumotachograph. Optical CO 2 calibration and zero fl ow were performed before each measurement. The instrumental dead space (mouthpiece plus pneumotachograph and infrared cell chamber) was 18 ml. Pneumotachograph linearity was confi rmed in the experimental range of fl ows, with increasing static fl ows measured by means of a rotameter (Collins, Braintree, Mass, USA). Expiratory fl ow and volume are expressed in BTPS conditions. Response characteristics of mainstream capnograph, as well as the validity of optical calibration, was determined by fl owing a gas mixture containing 5% (in) or 0% (out) CO 2 in air by means of a syringe at step changing fl ow rates in the range of the physiological rates. Delay between fl ow and capnographic signal and capnograph time constant were determined by analyzing the system's step response between 5% and 0% CO 2 in air. In all cases delay was measured as the time elapsed between the beginning of fl ow transition according to the pneumotachographic recording, and the breakpoint of the capnographic recording. Average delay was 58.9 ± 16.2 ms. Time constant was determined as the time to reach 63.2% of the total step response, and was 24.4 ± 2.35 ms. Capnographic signal was time shifted according to the time delay. Measurements: Capnographic recording was always performed before spirometry. Subjects were sitting during the recording procedure, breathing through a mouthpiece and with a nose clip. After two to three minutes of stable breath, CO 2 and fl ow signals were continuously recorded for two more minutes, digitalised at sampling frequency of 100 Hz and stored in magnetic media. Forced spirometry was performed with patient in standing position by means of a Fleisch pneumotachograph (GS-System, Collins, Braintree, MA, USA) according to ATS/ERS Standardization of Spirometry (ATS/ERS, http://www.thoracic.org/sections/ publications/statements/pages/pfet/pft2.html, update 2006). Spirometry was processed by GS software, and results expressed in BTPS conditions. To accept spirometry results, at least three manoeuvres with a reproducibility of 5% and a difference between the best and second best FEV 1 and FVC below 150 ml had to be recorded. A maximum of eight forced expiratory manoeuvres were performed. Maximal values of forced expiratory fl ow in one second (FEV 1 ), Forced Vital Capacity (FVC) and Maximal Mid Expiratory Flow between 25 and 75% of FVC (MMEF) were retained. The minimum time between manoeuvres was three minutes (of longer if requested by the patient). Spirometric manoeuvres were repeated 15 minutes after inhalation of 400 μg of salbutamol by means of a spacing chamber. According to recorded observations, time consumption by spirometric tests oscillated between about 20 minutes (the fastest) and 50 minutes (the slowest) plus the time consumed by the reversibility test. Predicted spirometric values were calculated from age, height and sex according to Roca et al (1986) .
Volumetric capnography parameters: A recording containing a minimum of fi fteen complete breathing cycles, at a minimal tidal volume of 150 ml was processed for every patient. Every cycle was identifi ed from the pneumotachographic signal, isolated and analysed separately by a computer procedure. Cycles not accepted for measurements were those with a P ET CO 2 5 mmHg lower or higher than the average P ET CO 2 . Also discarded were cycles with a tidal volume above or below 25% of average V T . Final results give the average of the measurements done on seven to fi fteen cycles for each patient.
End tidal CO 2 fractional concentration (F ET CO 2 ): to avoid the artefact of cardiac oscillations, F ET CO 2 was measured on the CO 2 elimination (VCO 2 ) versus expired volume (V) curve [VCO 2 = ∫F E CO 2 ·dV], as the linear slope between expired volume and VCO 2 of the segment defi ned by the end expiratory 10% of the total number of expiratory samples of each breath ( Figure 1 ). End-tidal partial pressure of CO 2 (P ET CO 2 ) was calculated from barometric pressure (P B ) as: F ET CO 2 ·(P B -P H2O ).
Bohr Dead Space (V D
Bohr
) was calculated according to classical principles, assuming that end-tidal fraction of CO 2 represents alveolar fractional concentration in the equation:
where V E CO 2 is the CO 2 eliminated by breath. Pre-interface expirate (PIE) was calculated according to Wolff and Brunner's method (Wolff and Brunner 1984) . In short, the volume expired when CO 2 has reached half of the end-expiratory value is doubled, the rest of the points are excluded from further analysis. Then the fi rst derivative of the signal (dF E CO 2 /dV) is plotted against the volume, and the mean of this normalized distribution function is calculated. The volume at which this mean value is obtained represents the minimal mean volume of the convective airways, also called the pre-interface expirate or PIE (Wolff and Brunner 1984) . Physiologically speaking, PIE represents the expired volume at which the interface between airways and alveolar gas is appreciated at airways opening.
Phase III slope (Sl III ): the curve between PIE and V T is divided into four segments. According to Åström et al (2000) , Sl III was calculated as the slope of the linear regression between F E CO 2 and Volume for the two central segments.
Series dead space (V D ser ): The curve was corrected for the Sl III between PIE and end tidal volume. From the corrected new curve, serial dead space volume (V D ser ) was calculated by the equal area method. This procedure prevents overcorrection of phase II (Åström et al 2000) . Airways dead 
Index of Alveolar Inhomogeneity (IAH):
According to previous studies (Kars et al 1995; Romero 2001 ) the difference between V D ser and V D Bohr is mainly due to impairment of regional distribution, which distorts the curve beyond PIE. An index of heterogeneity was calculated by relating both magnitudes according to:
Index of Ventilatory Effi ciency (IVE): Alveolar exhaled volume or V AE was determined from the VCO 2 versus expired volume or VCO 2 (V) curve, according to previous studies (Romero et al 1997; Blanch et al 1999) . In short, after the linear fi tting of the last end-expiratory segment previously described, the slope of this curve was decreased by 6% by pivoting on the end expiratory point. The new straight line crosses the VCO 2 (V) curve at a single point. The volume between this and the end-expiratory point corresponds to V AE (Figure 2 ). This volume tends to decrease as serial contamination of alveolar gas, heterogeneity, and phase II increase. As V AE directly depends on V T and V D ser , it seemed appropriate to express it in relation to these magnitudes. An index of ventilatory effi ciency (IVE) has been calculated as follows:
We used a 6% change in end tidal slope of VCO 2 (V) curve rather than the 5% used in previous studies in ventilated patients, because we have observed less variability in spontaneously breathing patients when using 6% (CVar% ± SD: 9.14 ± 3.34, and 10.98 ± 4.16 at 6% and 5% respectively. N = 16 patients, twenty consecutive cycles each). Statistical analysis: tests of normality (KolmogorofSmirnof) and homogeneity of variances (Levene homocedasticity test) were applied to data prior to deciding which test to use to compare the groups identifi ed according to GOLD classifi cation. For variables normally distributed, and with homogeneous variances, ANOVA analysis was performed. Tidal volume was added as covariant when necessary. If normality and homocedasticity tests failed at an error of 5%, the Kruskal-Walis rank test was applied to evaluate the differences between groups.
A multivariate model including Height, Body Mass Index, age, FEV 1 %pred, Tidal volume and MMEF%pred was used to determine the association of capnography parameters with functional data, and the possible confounding effect of factors relatively independent of respiratory functional abnormalities.
Receiver operating characteristic (ROC) curve analysis was performed to test the ability of each volumetric capnography parameter to detect the different levels of disease characterised by the GOLD Stages. The analysis was performed by cutting-off the population at increasing GOLD Stages of the disease. For each Stage Level, each parameter, considered as one-class classifi er, was progressively increased or decreased in step values (threshold changes). Sensitivity (Se) and specifi city (Sp) were calculated for each threshold change and expressed as a percentage. For each parameter at every stage ROC curves were constructed by plotting sensitivity against the false positive rate (100-specifi city). The area under the curve (AUC) and confi dence intervals at 95% were calculated to determine the degree and limits of accuracy of the curves, allowing paired comparisons. To determine cut-off points for each parameter at every stage, we calculated the point at which sensitivity equals specifi city (Se = Sp). Positive and Negative Predicted Values were calculated using Bayes theorem (Greiner and Gardner 2000) based on COPD prevalence observed by Kornmann et al (2003) at stages levels II, III and IV, and internal prevalence at stage 0. MedCalc ® and SPSS ® statistical packages were used for statistical analysis. Table 2 shows the descriptive statistics (mean, standard deviation) of capnography parameters in the COPD groups, as well as statistical data from ANOVA test. Variables ΔSl III and IVE did not meet the criteria of homocedasticity, and the Kruskal-Wallis test was applied. Group I was excluded, because it had only one subject. Although no signifi cant between groups difference was observed for V T , this parameter was used as covariant in the ANOVA analysis because of the documented tidal dependence of capnography variables (Åström et al 2000; Kornmann et al 2003) , and the high dispersion of V T . In Table II values of F (or χ 2 ) and P are given for between groups difference (F(χ 2 ) group , and P group ) and V T covariant effect (F cov , and P cov ). V D aw showed no signifi cant between-groups difference, but did show high dependence on V T . P ET CO 2 showed mainly group, but also some V T dependence. V D Bohr /V T showed both group and tidal volume dependence. When corrected for predicted value, however, (Δ = real-predicted, ΔV D Bohr /V T ) the covariant effect disappeared, but the group effect was maintained. Finally, IAH showed strong group but no V T dependence. Table 3 shows the results of the multivariate linear regression. Signifi cance P gives the probability associated to the rejection of the null hypothesis stating that the regression coeffi cient (Coeff) for a given independent variable is different from zero, at an alpha error below 5%. Variables in the equation (P < 0.05) are marked in bold. The Beta statistic or regression coeffi cient for typifi ed variables, allows a non dimensional comparison of the degree of association between dependent and independent variables. The narrowest association between FEV 1 %pred and capnography parameters was observed for IAH. This association was not confounded by other associations with the independent variables considered. In contrast, ΔV D Bohr /V T showed some extra dependence on age, but its association with FEV 1 %pred was still high. ΔSl III also showed a good correlation with FEV 1 %pred, but was greatly confounded by a high dependence on V T . Finally IVE was well defi ned by a model including FEV 1 %pred, MMEF%pred, and age. Using capnography parameters as independent variables, FEV 1 % pred was well defi ned (R = Table 4 shows the numerical analysis of the ROC curves, including AUC with 95% confi dence intervals, the cut-off value at which sensitivity equals specifi city, the value of sensitivity (or specifi city) at this cut-off, positive predicted value (PPV), and negative predicted value (NPV) calculated either from internal prevalence at stage level 0, or from the cumulative prevalence calculated from Kornmann et al (2003) for the remaining stage levels. A visual inspection of the ROC curves in Figure 3 shows that IAH and IVE seem more accurate than Sl III , and ΔV /V T at stage IV. Sensitivity (and specifi city) was similar and higher than 80% at all threshold levels for IAH, and IVE. In all cases PPV decreased with the threshold level of the disease, and the opposite was observed for NPV. The positive likelihood ratio (PLR) (ratio between the probability of observing the test result in diseased individuals, and the probability of observing the same result in non-diseased individuals) was globally high in IAH, followed by IVE, and ΔSLIII but only at stage IV.
Results
Discussion
According to our results, volumetric capnography parameters seem to be a good tool to determine the degree of functional involvement in COPD patients. It is generally considered that volumetric capnography refl ects the degree of pulmonary regional homogeneity in relation to gas exchange (Wolff and Brunner 1984; Fletcher and Jonson 1984; Hoffbrand 1966) . From this point of view it seems reasonable to expect that volumetric capnography will refl ect the progression of alveolar heterogeneity in parallel with that of the disease. Previous studies have shown some relationships between functional involvement in obstructive lung disease and specifi c indices obtained either from time based capnography (Toulou 1966; Smidt 1976; Worth 1986; You et al 1992) or from volumetric capnography in humans (Kars et al 1995; Kars et al 1997) and horses (Herholz et al 2002) . However, no systematic analysis of the diagnostic capabilities of volumetric capnography in COPD patients has been carried on until now in humans. Recent technical and conceptual advances have allowed anticipation of better perspectives for clinical applications of capnography. Nowadays, we can avoid this problem by taking into account the interface expired (Kars et al 1997; Åström et al 2000; Romero et al 1997) . In fact, the fi nding that V D aw , calculated according to Wolff and Brunner (1984) , is unrelated to the disease stage in COPD supports this hypothesis.
On the volumetric capnography parameters
Another factor that has limited the clinical use of volumetric capnography is the tidal dependence of the more usual capnography parameters. The use of predicted values means tidal dependence can be smoothed for V D Bohr /V T , by subtracting the predicted value. A better result is obtained by using a common mode rejection ratio: IAH to completely eliminates the tidal dependence of V D Bohr by referring it to V T -V D aw (Equation 2). IVE, based on the alveolar ejection volume (V AE ) measured on the VCO 2 (V) curve, also uses V T -V D aw as reference eliminate the tidal dependence of V AE . Both IAH and IVE parameters are related to functional troubles expressed during the alveolar phase of the capnogram. They are, therefore, physiologically related to regional distribution impairment as has been suggested by previous studies on normal subjects and COPD patients (Wilschut et al 1999; Hoffbrand 1966) ; however, the strong tidal dependence of Sl III could not be corrected even after subtraction of the predicted value calculated from tidal volume.
In 1997 /V T has shown a signifi cant correlation with FEV 1 % pred. In the multivariate model we have used, however, age is signifi cantly correlated with ΔV D Bohr /V T , a fact that was not noticed by Kars (1997) in COPD patients, or by Åström (2000) in normal subjects. In the study by Kars, only simple regressions were performed. Perhaps the age dependence we have observed is a surrogate dependence on the clinical evolution of the disease. Unfortunately, there is no way to verify this hypothesis from our present data.
ROC curves analysis
In order to obtain an estimation of the diagnostic accuracy of each parameter, as well as to determine the cut-off for each stage level of the disease, we have performed a receiver operating characteristics (ROC) curve analysis. A reliable defi nition of the disease and a good estimation of its prevalence, are the key elements for using ROC curves with a high degree of statistical power. (2003). Because their results are somewhat different from the internal prevalence calculated in our population, they have been used to obtain the cumulated prevalence for Positive and Negative Predicted Values and Likelihood Ratio calculations, except for Stage 0 level which does not represent a true prevalence of COPD disease, but simply a cut-off point for a reference population of ex-smokers (cessation for more than 10 years) with no clinical symptoms. Our population was not chosen to calculate the prevalence of COPD and that is why Stage Level 0 ROC Predicted Values and Likelihood Ratio do not correspond to the social prevalence of the disease. Furthermore, the stage-related variation of PPV and NPV may be infl uenced by their prevalence-dependence because we have used the cumulative prevalence in the ROC curve analysis. In contrast, sensitivity and specifi city values, AUC and cut-off points, which are prevalence-independent are therefore valid for all stages, including stage 0.
The area under the ROC curve (AUC) is a global summary statistic of diagnostic accuracy. According to an arbitrary guideline (based on a suggestion by Swets in 1988) , it is possible to distinguish between non-informative (AUC = 0.5), less accurate (0.5 Ͻ0.7 Յ0.9), highly accurate (0.9 ϽAUC Ͻ1) and perfect tests (AUC = 1). It has been recognised that AUC is equivalent to the probability that a randomly drawn individual from the positive reference sample has a higher (or lower) test value than a randomly drawn individual from the negative reference sample. As AUC gives equal weighting to sensitivity and specifi city, we have considered the point at which specifi city equals sensitivity as the cut-off point for all stages. However, other criteria could be used if we consider, for instance, the misclassifi cation cost (False Positive and False Negative Cost, CFP and CFN respectively), which require quantifi cation of the consequences of misclassifi cation . Without better information we have a priori considered that CFP = CFN, and we have given equal weight to sensitivity and specifi city.
In a previous study Herholtz et al (2002) studied the diagnostic value of volumetric capnography parameters in a population of horses suffering from recurrent airways obstruction (a veterinary equivalent of COPD in horses). In their study the best accuracy was obtained for V D Bohr /V T (AUC = 0.70, Se = Sp = 63%) in the staging between without symptoms and with symptoms horses, equivalent to our stage 0 for which we have obtained nearly identical results using ΔV D Bohr /V T (AUC = 0.68, Se = Sp = 63%). However practically all our AUC have been over 0.7.
In conclusion, capnography parameters seem to be useful for staging COPD patients when spirometry is diffi cult to perform because of technical or clinical constraints. Capnography is an easy-to-perform technique that requires no special effort or particular knowledge of the manoeuvre, and can be performed in severely disabled patients. It can be used as an alternative test to diagnose the severity of functional impairment in these patients. The Index of Alveolar Heterogeneity seems to be the best parameter for use in clinical practice.
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